PMID- 29802070
OWN - NLM
STAT- MEDLINE
DCOM- 20190305
LR  - 20190305
IS  - 1876-4754 (Electronic)
IS  - 1876-4754 (Linking)
VI  - 11
IP  - 5
DP  - 2018 Sep-Oct
TI  - BDNF plasma levels and genotype in depression and the response to 
      electroconvulsive therapy.
PG  - 1123-1131
LID - S1935-861X(18)30158-X [pii]
LID - 10.1016/j.brs.2018.05.011 [doi]
AB  - BACKGROUND: Brain derived neurotrophic factor (BDNF) has been implicated in the 
      pathophysiology of depression and the antidepressant response. Electroconvulsive 
      therapy (ECT) is reported to increase BDNF levels in blood, though only a small 
      number of studies have been conducted to date. OBJECTIVE: Our objectives were to: 
      1) compare plasma BDNF levels in medicated patients with depression and controls; 
      2) assess the effect of ECT on plasma BDNF levels in medicated patients with 
      depression; 3) explore the relationship between plasma BDNF levels and the 
      Val66Met (rs6265) BDNF polymorphism; and 4) examine the relationship between 
      plasma BDNF levels and clinical symptoms and outcomes with ECT. METHODS: Plasma 
      BDNF levels were analyzed in samples from 61 medicated patients with a major 
      depressive episode and 50 healthy controls, and in patient samples following a 
      course of ECT. Fifty-two samples from the depressed patient group were genotyped 
      for the Val66Met BDNF polymorphism. RESULTS: There was no difference in plasma 
      BDNF levels between the control and depressed groups, and there was no difference 
      in plasma BDNF levels in patients following treatment with ECT. In line with 
      previous reports, we show that, in medicated patients with depression, 
      Met-carriers had higher plasma BDNF levels than Val-carriers, though genotype was 
      not related to clinical response. We found no association between plasma BDNF 
      levels and depression severity or the clinical response to ECT. CONCLUSIONS: Our 
      results suggest that plasma BDNF does not represent a suitable candidate 
      biomarker for determining the therapeutic response to ECT.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Ryan, Karen M
AU  - Ryan KM
AD  - Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, 
      Ireland; Department of Psychiatry, St. Patrick's University Hospital, Trinity 
      College Dublin, Dublin, Ireland.
FAU - Dunne, Ross
AU  - Dunne R
AD  - Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, 
      Ireland; Department of Psychiatry, St. Patrick's University Hospital, Trinity 
      College Dublin, Dublin, Ireland.
FAU - McLoughlin, Declan M
AU  - McLoughlin DM
AD  - Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, 
      Ireland; Department of Psychiatry, St. Patrick's University Hospital, Trinity 
      College Dublin, Dublin, Ireland. Electronic address: d.mcloughlin@tcd.ie.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180518
PL  - United States
TA  - Brain Stimul
JT  - Brain stimulation
JID - 101465726
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Brain-Derived Neurotrophic Factor/*blood/genetics
MH  - Depressive Disorder, Major/*blood/genetics/therapy
MH  - *Electroconvulsive Therapy
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Polymorphism, Single Nucleotide
OTO - NOTNLM
OT  - Antidepressant
OT  - BDNF
OT  - Depression
OT  - Electroconvulsive therapy
OT  - Plasma
OT  - rs6265
EDAT- 2018/05/29 06:00
MHDA- 2019/03/06 06:00
CRDT- 2018/05/27 06:00
PHST- 2018/01/19 00:00 [received]
PHST- 2018/04/30 00:00 [revised]
PHST- 2018/05/15 00:00 [accepted]
PHST- 2018/05/29 06:00 [pubmed]
PHST- 2019/03/06 06:00 [medline]
PHST- 2018/05/27 06:00 [entrez]
AID - S1935-861X(18)30158-X [pii]
AID - 10.1016/j.brs.2018.05.011 [doi]
PST - ppublish
SO  - Brain Stimul. 2018 Sep-Oct;11(5):1123-1131. doi: 10.1016/j.brs.2018.05.011. Epub 
      2018 May 18.